氨磷汀联合GP方案对晚期乳腺癌患者近期疗效和化疗不良反应的影响

Effect of Amifostine combined with GP Regimen on the Short-term Efficacy and Adverse Reactions of Chemotherapy in Patients with Advanced Breast Cancer

目的:分析氨磷汀联合吉西他滨+顺铂(GP)方案对晚期乳腺癌患者近期疗效和化疗不良反应的影响。方法:回顾性分析2017年7月至2018年12月本院66例经病理学、细胞学确诊为晚期女性乳腺癌患者的临床资料,分为对照组(30例)给予GP方案,联合组(36例)采取氨磷汀联合GP方案进行治疗。比较两组患者近期疗效和化疗不良反应的发生情况。结果:两组患者治疗总有效率和疾病控制率的比较,均无明显差异(均P>0.05)。两组恶心呕吐、头晕、肝功能异常和肾功能异常发生率的比较,均无明显差异(均P>0.05);但联合组周围神经毒性和骨髓抑制发生率较对照组明显下降(均P<0.05)。结论:氨磷汀联合GP方案治疗晚期乳腺癌患者的近期疗效与单用GP方案相当,但氨磷汀联合GP方案可有效降低周围神经毒性和骨髓抑制发生率,且不会引起严重化疗不良反应,患者具有良好的耐受性。

Objective: To analyze the effect of amifostine combined with gemcitabine + cisplatin(GP) regimen on short-term efficacy and adverse reactions of chemotherapy in patients with advanced breast cancer. Methods: The clinical data of 66 patients with advanced breast cancer diagnosed by pathology and cytology from July 2017 to December 2018 were analyzed retrospectively. 66 patients were divided into control group(30 cases) receiving GP treatment and combined group(36 cases) treated by amifostine combined with GP. The short-term efficacy and adverse reactions of chemotherapy were compared between the two groups. Results: There was no significant difference in total effective rate and disease control rate between the two groups(both P> 0.05). There was no significant difference in the incidence of nausea, vomiting, dizziness, liver dysfunction and renal dysfunction between the two groups(all P>0.05), but the incidence rate of peripheral neurotoxicity and myelosuppression in the combined group was significantly lower than that in the control group(both P<0.05). Conclusion: The short-term efficacy of amifostine combined with GP regimen in the treatment of advanced breast cancer is similar to that of GP regimen alone, but amifostine combined with GP regimen can effectively decrease the incidence rate of peripheral nerve toxicity and myelosuppression, and does not cause serious adverse reactions of chemotherapy, with good tolerance of patients.